Patents by Inventor Suguru UENO

Suguru UENO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HER3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20220172420
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Application
    Filed: February 10, 2022
    Publication date: June 2, 2022
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore HETTMANN, Reimar ABRAHAM, Sabine BLUM, Suguru UENO
  • Anti-HER3 antibody-drug conjugate
    Patent number: 11298359
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 12, 2022
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore Hettmann, Reimar Abraham, Sabine Blum, Suguru Ueno
  • TREATMENT OF HER3-MUTATED CANCER BY ADMINISTRATION OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20220072144
    Abstract: A therapeutic agent for HER3-mutated cancer containing an anti-HER3 antibody-drug conjugate as an active ingredient and/or a method of treatment for cancer, the method including administering an anti-HER3 antibody-drug conjugate to a subject determined to have HER3-mutated cancer.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 10, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kumiko KOYAMA, Yoshinobu SHIOSE, Suguru UENO
  • Anti-HER3 antibody-drug conjugate
    Patent number: 10383878
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: August 20, 2019
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore Hettmann, Reimar Abraham, Sabine Blum, Suguru Ueno
  • ANTI-HER3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20190151328
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Application
    Filed: January 31, 2019
    Publication date: May 23, 2019
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore HETTMANN, Reimar ABRAHAM, Sabine BLUM, Suguru UENO
  • ANTI-HER3 ANTIBODY-DRUG CONJUGATE
    Publication number: 20170021031
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Application
    Filed: October 4, 2016
    Publication date: January 26, 2017
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, U3 PHARMA GMBH
    Inventors: Thore HETTMANN, Reimar ABRAHAM, Sabine BLUM, Suguru UENO